Cargando…

Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report

Chemotherapy combined with targeted therapy is a first-line and second-line treatment for metastatic colorectal cancer(mCRC), which has brought survival benefits to mCRC patients, however, disease progression is inevitable. More than 60% of patients still needed third-line treatment after the progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qizheng, Zhang, Xia, Fan, Buqun, Yang, Yudie, Cui, Xiaonan, Zhang, Jie, Jiang, Kaiteng, Zhang, Chunxia, Zhang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748473/
https://www.ncbi.nlm.nih.gov/pubmed/36531025
http://dx.doi.org/10.3389/fonc.2022.978005
_version_ 1784849832264859648
author Li, Qizheng
Zhang, Xia
Fan, Buqun
Yang, Yudie
Cui, Xiaonan
Zhang, Jie
Jiang, Kaiteng
Zhang, Chunxia
Zhang, Bin
author_facet Li, Qizheng
Zhang, Xia
Fan, Buqun
Yang, Yudie
Cui, Xiaonan
Zhang, Jie
Jiang, Kaiteng
Zhang, Chunxia
Zhang, Bin
author_sort Li, Qizheng
collection PubMed
description Chemotherapy combined with targeted therapy is a first-line and second-line treatment for metastatic colorectal cancer(mCRC), which has brought survival benefits to mCRC patients, however, disease progression is inevitable. More than 60% of patients still needed third-line treatment after the progress of second-line treatment. After the failure of second-line chemotherapy, treatment compliance and the physical tolerance of patients both decrease. Therefore, choosing an appropriate third-line treatment regimen is key to prolonging survival and improving quality of life. As a novel cytotoxic antitumor drug, trifluridine/tipiracil (TAS-102) is composed of trifluridine (FTD) and tipiracil hydrochloride (TPI). FTD can directly bind to the DNA of cancer cells to cause DNA dysfunction, thereby exerting antitumor effects. TPI can inhibit the degradation of FTD, thereby increasing its cytotoxicity. The few side effects of TAS-102 has become an important reason why clinicians present it as a treatment option to the patient for consideration, clinical trial data for progression free survival are lacking. The exploration of third-line treatment regimens with drug combinations has attracted much attention. This article reports a case of metastatic colon cancer (RAS/BRAF wild type, pMMR/Non-MSI-H), after failure of first-line and second-line therapies, the patient was eventually treated with anlotinib combined with TAS-102 as the third-line treatment. The treatment has shown good efficacy, with a long PFS benefit for more than 20 months and mild adverse reactions. This case reports demonstrates that anlotinib combined with TAS-102 is a promising third-line treatment regimen for refractory mCRC, and provides proof-of-concept for the clinical exploration of optimal third-line combination treatment regimens.
format Online
Article
Text
id pubmed-9748473
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97484732022-12-15 Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report Li, Qizheng Zhang, Xia Fan, Buqun Yang, Yudie Cui, Xiaonan Zhang, Jie Jiang, Kaiteng Zhang, Chunxia Zhang, Bin Front Oncol Oncology Chemotherapy combined with targeted therapy is a first-line and second-line treatment for metastatic colorectal cancer(mCRC), which has brought survival benefits to mCRC patients, however, disease progression is inevitable. More than 60% of patients still needed third-line treatment after the progress of second-line treatment. After the failure of second-line chemotherapy, treatment compliance and the physical tolerance of patients both decrease. Therefore, choosing an appropriate third-line treatment regimen is key to prolonging survival and improving quality of life. As a novel cytotoxic antitumor drug, trifluridine/tipiracil (TAS-102) is composed of trifluridine (FTD) and tipiracil hydrochloride (TPI). FTD can directly bind to the DNA of cancer cells to cause DNA dysfunction, thereby exerting antitumor effects. TPI can inhibit the degradation of FTD, thereby increasing its cytotoxicity. The few side effects of TAS-102 has become an important reason why clinicians present it as a treatment option to the patient for consideration, clinical trial data for progression free survival are lacking. The exploration of third-line treatment regimens with drug combinations has attracted much attention. This article reports a case of metastatic colon cancer (RAS/BRAF wild type, pMMR/Non-MSI-H), after failure of first-line and second-line therapies, the patient was eventually treated with anlotinib combined with TAS-102 as the third-line treatment. The treatment has shown good efficacy, with a long PFS benefit for more than 20 months and mild adverse reactions. This case reports demonstrates that anlotinib combined with TAS-102 is a promising third-line treatment regimen for refractory mCRC, and provides proof-of-concept for the clinical exploration of optimal third-line combination treatment regimens. Frontiers Media S.A. 2022-11-30 /pmc/articles/PMC9748473/ /pubmed/36531025 http://dx.doi.org/10.3389/fonc.2022.978005 Text en Copyright © 2022 Li, Zhang, Fan, Yang, Cui, Zhang, Jiang, Zhang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Qizheng
Zhang, Xia
Fan, Buqun
Yang, Yudie
Cui, Xiaonan
Zhang, Jie
Jiang, Kaiteng
Zhang, Chunxia
Zhang, Bin
Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
title Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
title_full Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
title_fullStr Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
title_full_unstemmed Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
title_short Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
title_sort anlotinib combined with tas-102 as the third-line treatment for a patient with metastatic colon cancer: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748473/
https://www.ncbi.nlm.nih.gov/pubmed/36531025
http://dx.doi.org/10.3389/fonc.2022.978005
work_keys_str_mv AT liqizheng anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport
AT zhangxia anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport
AT fanbuqun anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport
AT yangyudie anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport
AT cuixiaonan anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport
AT zhangjie anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport
AT jiangkaiteng anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport
AT zhangchunxia anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport
AT zhangbin anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport